Liposomal Amphotericin B in Treating Deep Fungal Infections: A Clinical Study on the Efficacy and Safety

OBJECTIVE To evaluate the efficacy and safety of liposomal amphotericin B(LAB) in treating deep fungul infections. METHODS In this multicenter, randomized comparative open study, 30 patients (T group) and 55 patients (O group) were given liposomal amphotericin B intrevenously, 31 patients (B group) were given amphotericin B intravenously. RESULTS The cure rate (T group vs B group) was 63.3% vs 50.0%, the effective rate (T group vs B group) were 96.7% vs 86.7%, respectively, there was no ststistically significant difference between the two groups; in patients with central nervous system fungal infections; MIC 50 and MIC 90 of T group were 0.5mg/L and 1mg/L, and that of B group were 0.5mg/L and 2mg/L, respectivelly; the rate of adverse effect in T group(60.0%) was lower than that of B group. CONCLUSIONS The clinical efficacy of liposomal amphotericin B is as good as that of amphotericin B, the adverse reaction rate of liposomal amphotericin B is lower than that of amphotericin B.